Acrobiosystems Co News
News
0
Ticker
301080.SZ
ISIN
CNE100004S13
Acrobiosystems Co Eulerpool-uutiset
Acrobiosystems Co-osakkeen uutiset
Acrobiosystems Co-osaketta seuraa lukuisia toimittajia ja sijoittajia maailmanlaajuisesti. Kokoamme tämän uusimmat Acrobiosystems Co-uutiset tähän.
Acrobiosystems Co-osakkeen lehdistötiedotteet
Acrobiosystems Co julkaisee säännöllisesti yrityksen verkkosivuilla sijoittajille merkityksellisiä tiedotteita.
Acrobiosystems Co News 2026
Tällä sivulla on kaikki Acrobiosystems Co osakkeen (301080.SZ, ISIN: CNE100004S13) ajankohtaiset uutiset, analyysit ja lehdistötiedotteet. Tämä sisältää Eurpool-uutiset, yhtiöanalyysin ja viralliset lehdistötiedotteet. Tietoja päivitetään säännöllisesti, jotta sijoittajille saataisiin täydellinen yleiskatsaus Acrobiosystems Co:n uusimmista kehityksestä.
Acrobiosystems Co Osake
Acrobiosystems Co Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development.